| Name | Title | Contact Details |
|---|---|---|
Chris Shively |
Director Of Information Technology | Profile |
biBerk helps small-business owners find the right insurance policies for their needs without extra costs and hassles. As a part of Warren Buffetts Berkshire Hathaway insurance group, our approach is to help you find the coverage thats right for your business right now. As your business grows, we offer the added insurance products that you need so your coverage grows with you. biBerk can help you with all your small business insurance needs, including: - Workers Compensation - Professional Liability (E&O) - General Liability - Property & Liability (BOP) - Commercial Auto - Umbrella Were also backed by an expert customer service team that can answer any question you throw at them. Well help you find the right insurance policy for your small business. Rated A++ by A.M. Best Company and AAA by Standard & Poors Corporation
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Katzke & Morgenbesser LLP is a boutique law firm specializing in a broad array of executive compensation-related matters. We have extensive experience representing senior corporate executives and other management employees, companies, boards of directors and compensation committees with respect to complex and sensitive employment, severance, retirement, consulting, equity and other incentive compensation arrangements. Such representations are often in connection with public and private business combinations, acquisitions and divestitures for corporations and partnerships. Each of our named partners has more than twenty-five years of experience in executive compensation. As former partners at major New York and international law firms, we are uniquely situated to provide independent, high quality, focused and responsive service without the likelihood of potential conflicts of interest. Our Firm counsels clients primarily with respect to executive compensation-related matters. We routinely provide consulting, drafting and negotiation guidance to individuals, companies, boards of directors and compensation committees on a wide range of topics, including the following areas: - Employment, Severance, Retention and Consulting Agreements - Non-Competition, Non-Solicitation and other Restrictive Covenants - Equity and Cash-based Incentive Compensation - Deferred Compensation Arrangements - Partnership Arrangements - Retirement Arrangements/SERPs - Rabbi Trusts and other Funding/Financing Vehicles - Change in Control Programs and Arrangements - Code Section Section 409A Reviews - Advisory Services to Boards of Directors and Compensation Committees
At SIS, were proud to be leaders in collecting, analyzing and distributing the deepest data sets and insights to professional sports teams across MLB, NBA and NFL, while also partnering extensively with the leagues themselves. Our mission is to enrich and optimize the decision-making process for sports teams, sportsbooks, and sports fans. Our vision is to create an unparalleled platform of sporting data and insights through best-in-class technology, products, and partnerships. Our versatility, subject matter expertise, and desire to enhance our partners performance is at the core of what we do. As we enter the next chapter of our trajectory, we are keen to put our data and newfound products to use to improve the sports fan experience, while being a critical part of the supply chain. Our existing database offers unparalleled detail and is updated daily, not just for the 3 professional sports listed, but at the collegiate, international and minor league levels as well. We are also moving further into the real-time data space (for the above noted sports) and into new sports/leagues. A key differentiator for us relative to competition is our flexibility and ability to customize feeds, data points, etc based on specific needs of partners. Company chairman John Dewan founded the company with a group of partners in 2003. John has been a pioneer in sports statistics for more than 40 years and was the founder of STATS Inc. In April of 2021, Audeo Capital announced a significant investment into SIS. Shortly thereafter, a new CEO (Dan Hannigan-Daley) and VP of Product/Engineering (Will Hester) joined the organization following years of success at DraftKings.